Top

Published in:

01-06-2016 | Original Article

Intramyocardial delivery of VEGF₁₆₅ via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction

Authors: Hongling Zhu, Xuejun Jiang, Xiaoyan Li, Miaoyang Hu, Weiguo Wan, Ying Wen, Yiyu He, Xiaoxin Zheng

Published in: Heart and Vessels | Issue 6/2016

Abstract

Vascular endothelial growth factor (VEGF), an independent mitogen, has been reported to induce angiogenesis and thus attenuates the damage induced by myocardial infarction (MI). VEGF₁₆₅ is the most abundant and predominant isoform of VEGF. This study investigates whether this effect could be strengthened by local intramyocardial injection of VEGF₁₆₅ along with a novel biodegradable Dex-PCL-HEMA/PNIPAAm hydrogel and ascertains its possible mechanism of action. Rat models of myocardial infarction were induced by coronary artery ligation. Phosphate-buffered saline (PBS group), Dex-PCL-HEMA/PNIPAAm hydrogel (Gel group), phosphate-buffered saline containing VEGF₁₆₅ (VP group), and hydrogel containing VEGF₁₆₅ (VPG group) were injected into a peri-infarcted area of cardiac tissue immediately after myocardial infarction, respectively. The sham group was thoracic but without myocardial infarction. The injection of VEGF₁₆₅ along with a hydrogel induced angiogenesis, reduced collagen content and MI area, inhibited cell apoptosis, increased the level of VEGF₁₆₅ protein and the expression of flk-1 and flt-1, and improved cardiac function compared with the injection of either alone after MI in rats. The results suggest that injection of VEGF₁₆₅ along with a hydrogel acquires more cardioprotective effects than either alone in rat with MI by sustained release of VEGF₁₆₅, then may enhance the feedback between VEGF and its receptors flk-1 and flt-1.

Zhang BH, Guo CX, Wang HX, Lu LQ, Wang YJ, Zhang LK, Du FH, Zeng XJ (2014) Cardioprotective effects of adipokine apelin on myocardial infarction. Heart Vessels 29(5):679–689CrossRefPubMed

Sun Y, Weber KT (2000) Infarct scar: a dynamic tissue. Cardiovasc Res 46(2):250–256CrossRefPubMed

Colucci WS (1997) Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80(11A):15L–25LCrossRefPubMed

Mann DL (1999) Mechanisms and models in heart failure: a combinatorial approach. Circulation 100(9):999–1008CrossRefPubMed

Jiang XJ, Wang T, Li XY, Wu DQ, Zheng ZB, Zhang JF, Chen JL, Peng B, Jiang H, Huang C, Zhang XZ (2009) Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction. J Biomed Mater Res A 90(2):472–477CrossRefPubMed

Cabiati M, Martino A, Mattii L, Caselli C, Prescimone T, Lionetti V, Morales MA, Del Ry S (2014) Adenosine receptor expression in an experimental animal model of myocardial infarction with preserved left ventricular ejection fraction. Heart Vessels 29(4):513–519CrossRefPubMed

Tamura K, Nakajima H, Rakue H, Sasame A, Naito Y, Nagai Y, Ibukiyama C (1999) Elevated circulating levels of basic fibroblast growth factor and vascular endothelial growth factor in patients with acute myocardial infarction. Jpn Circ J 63(5):357–361CrossRefPubMed

Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E (1994) Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc Res 28(8):1176–1179CrossRefPubMed

Haynesworth SE, Baber MA, Caplan AI (1996) Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 166(3):585–592CrossRefPubMed

10.

Yin R, Feng J, Chen D, Wu H (2000) Serum levels of vascular endothelial growth factor in patients with angina pectoris and acute myocardial infarction. Chin Med Sci J 15(4):205–209PubMed

11.

Yin R, Feng J, Yao Z (2000) Dynamic changes of serum vascular endothelial growth factor levels in a rat myocardial infarction model. Chin Med Sci J 15(3):154–156PubMed

12.

Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N (2000) Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels 15(3):105–111CrossRefPubMed

13.

Kumagai M, Marui A, Tabata Y, Takeda T, Yamamoto M, Yonezawa A, Tanaka S, Yanagi S, Ito-Ihara T, Ikeda T, Murayama T, Teramukai S, Katsura T, Matsubara K, Kawakami K, Yokode M, Shimizu A, Sakata R (2015) Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. Heart Vessels. doi:10.1007/s00380-015-0677-x

14.

Yuan QY, Zhu ZW, Wang Z, Wang XM, Li XS, Huang J, Si LY (2012) A novel method of augmenting gene expression and angiogenesis in the normal and ischemic canine myocardium. Heart Vessels 27(3):316–326CrossRefPubMed

15.

Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM (1994) Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93(2):662–670CrossRefPubMedPubMedCentral

16.

Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK (1998) Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115(1):168–176 (discussion 176–167) CrossRefPubMed

17.

Yla-Herttuala S, Martin JF (2000) Cardiovascular gene therapy. Lancet 355(9199):213–222CrossRefPubMed

18.

Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246(4935):1306–1309CrossRefPubMed

19.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676CrossRefPubMed

20.

Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13(1):18–32CrossRefPubMed

21.

Post MJ, Laham R, Sellke FW, Simons M (2001) Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 49(3):522–531CrossRefPubMed

22.

Hughes GC, Biswas SS, Yin B, Coleman RE, DeGrado TR, Landolfo CK, Lowe JE, Annex BH, Landolfo KP (2004) Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF. Ann Thorac Surg 77(3):812–818CrossRefPubMed

23.

Davis ME, Hsieh PC, Takahashi T, Song Q, Zhang S, Kamm RD, Grodzinsky AJ, Anversa P, Lee RT (2006) Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci USA 103(21):8155–8160CrossRefPubMedPubMedCentral

24.

Salimath AS, Phelps EA, Boopathy AV, Che PL, Brown M, Garcia AJ, Davis ME (2012) Dual delivery of hepatocyte and vascular endothelial growth factors via a protease-degradable hydrogel improves cardiac function in rats. PLoS One 7(11):e50980CrossRefPubMedPubMedCentral

25.

Engel FB, Hsieh PC, Lee RT, Keating MT (2006) FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci USA 103(42):15546–15551CrossRefPubMedPubMedCentral

26.

Epstein SE, Kornowski R, Fuchs S, Dvorak HF (2001) Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 104(1):115–119CrossRefPubMed

27.

He YY, Wen Y, Zheng XX (2013) Jiang XJ (2013) Intramyocardial delivery of HMGB1 by a novel thermosensitive hydrogel attenuates cardiac remodeling and improves cardiac function after myocardial infarction. J Cardiovasc Pharmacol 61(4):283–290CrossRefPubMed

28.

Wan WG, Jiang XJ, Li XY, Zhang C, Yi X, Ren S, Zhang XZ (2014) Enhanced cardioprotective effects mediated by plasmid containing the short-hairpin RNA of angiotensin converting enzyme with a biodegradable hydrogel after myocardial infarction. J Biomed Mater Res A 102(10):3452–3458CrossRefPubMed

29.

Christman KL, Lee RJ (2006) Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 48(5):907–913CrossRefPubMed

30.

Dai W, Wold LE, Dow JS, Kloner RA (2005) Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol (JACC) 46(4):714–719CrossRef

31.

Hao X, Silva EA, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, Wardell E, Brodin LA, Mooney DJ, Sylven C (2007) Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 75(1):178–185CrossRefPubMed

32.

Leor J, Amsalem Y, Cohen S (2005) Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol Therapeut 105(2):151–163CrossRef

33.

Landa N, Miller L, Feinberg MS, Holbova R, Shachar M, Freeman I, Cohen S, Leor J (2008) Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 117(11):1388–1396CrossRefPubMed

34.

Kofidis T, Lebl DR, Martinez EC, Hoyt G, Tanaka M, Robbins RC (2005) Novel injectable bioartificial tissue facilitates targeted, less invasive, large-scale tissue restoration on the beating heart after myocardial injury. Circulation 112(9 Suppl):I173–I177PubMed

35.

Davis ME, Motion JP, Narmoneva DA, Takahashi T, Hakuno D, Kamm RD, Zhang S, Lee RT (2005) Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 111(4):442–450CrossRefPubMedPubMedCentral

36.

Luo D, Saltzman WM (2000) Synthetic DNA delivery systems. Nat Biotechnol 18(1):33–37CrossRefPubMed

37.

Wu DQ, Qiu F, Wang T, Jiang XJ, Zhang XZ, Zhuo RX (2009) Toward the development of partially biodegradable and injectable thermoresponsive hydrogels for potential biomedical applications. ACS Appl Mater Interfaces 1(2):319–327CrossRefPubMed

38.

Wang T, Wu DQ, Jiang XJ, Zhang XZ, Li XY, Zhang JF, Zheng ZB, Zhuo R, Jiang H, Huang C (2009) Novel thermosensitive hydrogel injection inhibits post-infarct ventricle remodelling. Eur J Heart Fail 11(1):14–19CrossRefPubMed

39.

Chen L, Mupo A, Huynh T, Cioffi S, Woods M, Jin C, McKeehan W, Thompson-Snipes L, Baldini A, Illingworth E (2010) Tbx1 regulates Vegfr3 and is required for lymphatic vessel development. J Cell Biol 189(3):417–424CrossRefPubMedPubMedCentral

40.

Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M (1996) VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 270(5 Pt 2):H1803–H1811PubMed

41.

Infanger M, Faramarzi S, Grosse J, Kurth E, Ulbrich C, Bauer J, Wehland M, Kreutz R, Kossmehl P, Paul M, Grimm D (2007) Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. Cardiovasc Pathol 16(5):291–299CrossRefPubMed

42.

Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43):26988–26995PubMed

43.

Roskoski R Jr (2008) VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 375(3):287–291CrossRefPubMed

44.

Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25CrossRefPubMed

45.

Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39(5):469–478CrossRefPubMed

46.

Yang XH, Man XY, Cai SQ, Yao YG, Bu ZY, Zheng M (2006) Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. Biochem Biophys Res Commun 349(1):31–38CrossRefPubMed

47.

Hashimoto E, Ogita T, Nakaoka T, Matsuoka R, Takao A, Kira Y (1994) Rapid induction of vascular endothelial growth factor expression by transient ischemia in rat heart. The Am J Physiol 267(5 Pt 2):H1948–H1954PubMed

Title: Intramyocardial delivery of VEGF165 via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction
Authors: Hongling Zhu
Xuejun Jiang
Xiaoyan Li
Miaoyang Hu
Weiguo Wan
Ying Wen
Yiyu He
Xiaoxin Zheng
Publication date: 01-06-2016
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 6/2016
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-015-0710-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Intramyocardial delivery of VEGF₁₆₅ via a novel biodegradable hydrogel induces angiogenesis and improves cardiac function after rat myocardial infarction

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

The wound healing response after implantation of a drug-eluting stent is impaired persistently in the long term

Clinical features of isolated dissections of abdominal aortic branches

Lower 1,5-anhydroglucitol is associated with adverse clinical events after percutaneous coronary intervention

Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study

Prescription patterns of oral anticoagulants for patients with non-valvular atrial fibrillation: experience at a Japanese single institution

Increased IL18 mRNA levels in peripheral artery disease and its association with triglyceride and LDL cholesterol levels: a pilot study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page